Skip to main content

Advertisement

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 5 of 11

  1. The polyether antibiotic Salinomycin (Sal) is regarded as an inhibitor of cancer stem cells. Its effectiveness on human colorectal cancer (CRC) cells in vitro has been demonstrated before. The aim of this stud...

    Authors: Johannes Klose, Jana Eissele, Claudia Volz, Steffen Schmitt, Alina Ritter, Shen Ying, Thomas Schmidt, Ulrike Heger, Martin Schneider and Alexis Ulrich

    Citation: BMC Cancer 2016 16:896

    Content type: Research article

    Published on:

  2. Neuroblastoma (NB) is a frequent pediatric tumor characterized by a poor prognosis where a majority of tumors progress despite intensive multimodality treatments. Autophagy, a self-degradative process in cells...

    Authors: Assila Belounis, Carine Nyalendo, Roxane Le Gall, Tina V. Imbriglio, Mohamed Mahma, Pierre Teira, Mona Beaunoyer, Sonia Cournoyer, Elie Haddad, Gilles Vassal and Hervé Sartelet

    Citation: BMC Cancer 2016 16:891

    Content type: Research article

    Published on:

  3. Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions ...

    Authors: Rong Biaoxue, Cai Xiguang, Liu Hua, Gao Wenlong and Yang Shuanying

    Citation: BMC Cancer 2016 16:888

    Content type: Research article

    Published on:

  4. Evaluate the anti-tumor activity of ozonide antimalarials using a chemoresistant neuroblastoma cell line, BE (2)-c.

    Authors: Don W. Coulter, Timothy R. McGuire, John G. Sharp, Erin M. McIntyre, Yuxiang Dong, Xiaofang Wang, Shawn Gray, Gracey R. Alexander, Nagendra K. Chatuverdi, Shantaram S. Joshi, Xiaoyu Chen and Jonathan L. Vennerstrom

    Citation: BMC Cancer 2016 16:867

    Content type: Research article

    Published on:

  5. Vorinostat, a histone deacetylase (HDAC) inhibitor, is a promising agent for cancer therapy. Combining vorinostat with cisplatin may relax the chromatin structure and facilitate the accessibility of cisplatin,...

    Authors: Chun-Hao Pan, Ying-Fang Chang, Ming-Shuo Lee, B-Chen Wen, Jen-Chung Ko, Sheng-Kai Liang and Mei-Chih Liang

    Citation: BMC Cancer 2016 16:857

    Content type: Research article

    Published on:

  6. Little is known about the roles of Notch signaling in cholangiocarcinoma (CC). The expression of hairy and enhancer of split 1 (Hes-1) has not been investigated yet in resected specimens of CC. Notch signaling...

    Authors: Shuichi Aoki, Masamichi Mizuma, Yayoi Takahashi, Yoichi Haji, Ryo Okada, Tomoya Abe, Hideaki Karasawa, Keiichi Tamai, Takaho Okada, Takanori Morikawa, Hiroki Hayashi, Kei Nakagawa, Fuyuhiko Motoi, Takeshi Naitoh, Yu Katayose and Michiaki Unno

    Citation: BMC Cancer 2016 16:854

    Content type: Research article

    Published on:

  7. Although brucea javanica oil liposomes (BJOLs) have been used clinically to treat ovarian cancer, its clinical efficacy is often limited by systemic side effects due to non-specific distribution. Luteinizing h...

    Authors: Hongxia Ye, Xiaojuan Liu, Jiangchuan Sun, Shenyin Zhu, Yi Zhu and Shufang Chang

    Citation: BMC Cancer 2016 16:831

    Content type: Research article

    Published on:

  8. Endometrial cancer is the most common cancer of the female reproductive tract.

    Authors: Anna Torres, Joanna Kozak, Agnieszka Korolczuk, Paulina Wdowiak, Ewa Domańska-Glonek, Ryszard Maciejewski and Kamil Torres

    Citation: BMC Cancer 2016 16:822

    Content type: Research article

    Published on:

    The Erratum to this article has been published in BMC Cancer 2016 16:939

  9. Triple-negative breast cancer (TNBC) has aggressive progression with poor prognosis and ineffective treatments. Selumetinib is an allosteric, ATP-noncompetitive inhibitor of MEK1/2, which has benn known as eff...

    Authors: Yan Zhou, Shuchen Lin, Kuo-Fu Tseng, Kun Han, Yaling Wang, Zhi-hua Gan, Da-liu Min and Hai-yan Hu

    Citation: BMC Cancer 2016 16:818

    Content type: Research article

    Published on:

  10. Previous studies have reported that eEF-2 kinase is associated with tumour cell sensitivity to certain therapies. In the present study, we investigated the relationship between eEF-2 kinase and lapatinib, a du...

    Authors: Lin Liu, PeiYu Huang, ZhiHui Wang, Nan Chen, Con Tang, Zhong Lin and PeiJian Peng

    Citation: BMC Cancer 2016 16:813

    Content type: Research article

    Published on:

  11. Hepatocellular carcinoma (HCC) is one of the most common malignant cancers worldwide and is associated with substantial mortality. Because HCCs have strong resistance to conventional chemotherapeutic agents, n...

    Authors: Jae-Woo Jang, Yeonhwa Song, Kang Mo Kim, Jin-Sun Kim, Eun Kyung Choi, Joon Kim and Haengran Seo

    Citation: BMC Cancer 2016 16:810

    Content type: Research article

    Published on:

  12. Cachexia is one of the most important causes of cancer-related death. Supplementation with branched-chain amino acids, particularly leucine, has been used to minimise loss of muscle tissue, although few studie...

    Authors: Laís Rosa Viana, Rafael Canevarolo, Anna Caroline Perina Luiz, Raquel Frias Soares, Camila Lubaczeuski, Ana Carolina de Mattos Zeri and Maria Cristina Cintra Gomes-Marcondes

    Citation: BMC Cancer 2016 16:764

    Content type: Research article

    Published on:

  13. Curcuminoids of the spice turmeric and their enhanced derivatives have much potential as cancer treatments. They act on a wide variety of biological pathways, including those regulating cell division and circa...

    Authors: Ashapurna Sarma, Vishal P. Sharma, Arindam B. Sarkar, M. Chandra Sekar, Karunakar Samuel and Michael E. Geusz

    Citation: BMC Cancer 2016 16:759

    Content type: Research article

    Published on:

  14. Although cis-diamminedichloro-platinum (CDDP) exhibits strong therapeutic effects in cancer chemotherapy, its adverse effects such as peripheral neuropathy, nephropathy, and vomiting are dose-limiting factors. Pr...

    Authors: Yoshihiro Seto, Fumiyasu Okazaki, Keiji Horikawa, Jing Zhang, Hitoshi Sasaki and Hideto To

    Citation: BMC Cancer 2016 16:756

    Content type: Research article

    Published on:

  16. Mutations in DNA damage response factors BRCA1 and BRCA2 confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors in breast and ovarian cancers. BRCA1/BRCA2-defective tumors can exhibit resistance t...

    Authors: Ruoxi Hong, Fei Ma, Weimin Zhang, Xiying Yu, Qing Li, Yang Luo, Changjun Zhu, Wei Jiang and Binghe Xu

    Citation: BMC Cancer 2016 16:725

    Content type: Research article

    Published on:

    The Erratum to this article has been published in BMC Cancer 2016 16:925

  17. Baicalein is a widely used Chinese herbal medicine derived from Scutellaria baicalenesis, which has been traditionally used as anti-inflammatory and anti-cancer therapy. In this study we examined the anti-tumour ...

    Authors: Mary-Clare Cathcart, Zivile Useckaite, Clive Drakeford, Vikki Semik, Joanne Lysaght, Kathy Gately, Kenneth J. O’Byrne and Graham P. Pidgeon

    Citation: BMC Cancer 2016 16:707

    Content type: Research article

    Published on:

  18. Iron is essential for cell replication, metabolism and growth. Because neoplastic cells have high iron requirements due to their rapid proliferation, iron depletion may be a novel therapeutic strategy for canc...

    Authors: Hirofumi Harima, Seiji Kaino, Taro Takami, Shuhei Shinoda, Toshihiko Matsumoto, Koichi Fujisawa, Naoki Yamamoto, Takahiro Yamasaki and Isao Sakaida

    Citation: BMC Cancer 2016 16:702

    Content type: Research article

    Published on:

  19. shRNA-mediated lethality screening is a useful tool to identify essential targets in cancer biology. Ovarian cancer (OC) is extremely heterogeneous and most cases are advanced stages at diagnosis. OC has a hig...

    Authors: Marianne K. Kim, Natasha Caplen, Sirisha Chakka, Lidia Hernandez, Carrie House, Georgios Pongas, Elizabeth Jordan and Christina M. Annunziata

    Citation: BMC Cancer 2016 16:678

    Content type: Research article

    Published on:

  20. Glioblastomas (GBMs) are highly malignant brain tumours with a poor prognosis, and current cytotoxic regimens provide only a limited survival benefit. The PI3K/Akt/mTOR pathway has been an attractive target fo...

    Authors: I. A. Netland, H. E. Førde, L. Sleire, L. Leiss, M. A. Rahman, B. S. Skeie, C. H. Gjerde, P. Ø. Enger and D. Goplen

    Citation: BMC Cancer 2016 16:657

    Content type: Research article

    Published on:

  21. We report on the results of a phase II clinical trial of Panagen (tablet form of fragmented human DNA preparation) in breast cancer patients (placebo group n = 23, Panagen n = 57). Panagen was administered as an ...

    Authors: Anastasia S. Proskurina, Tatiana S. Gvozdeva, Ekaterina A. Potter, Evgenia V. Dolgova, Konstantin E. Orishchenko, Valeriy P. Nikolin, Nelly A. Popova, Sergey V. Sidorov, Elena R. Chernykh, Alexandr A. Ostanin, Olga Y. Leplina, Victoria V. Dvornichenko, Dmitriy M. Ponomarenko, Galina S. Soldatova, Nikolay A. Varaksin, Tatiana G. Ryabicheva…

    Citation: BMC Cancer 2016 16:651

    Content type: Research article

    Published on:

  22. High expression levels of Inhibitors of Apoptosis Proteins (IAPs) have been correlated with poor cancer prognosis and block the cell death pathway by interfering with caspase activation. SMAC-mimetics are smal...

    Authors: Philippos Perimenis, Apostolos Galaris, Alexandra Voulgari, Margarita Prassa and Alexander Pintzas

    Citation: BMC Cancer 2016 16:624

    Content type: Research article

    Published on:

  23. Cyclophosphamide (CPA) can activate immunogenic tumor cell death, which induces immune-based tumor ablation and long-term anti-tumor immunity in a syngeneic C57BL/6 (B6) mouse GL261 glioma model when CPA is gi...

    Authors: Junjie Wu, Marie Jordan and David J. Waxman

    Citation: BMC Cancer 2016 16:623

    Content type: Research article

    Published on:

  24. The radiopharmaceutical 131I-meta-iodobenzylguanidine (131I-MIBG) is an effective treatment for neuroblastoma. However, maximal therapeutic benefit from 131I-MIBG is likely to be obtained by its combination with ...

    Authors: Donna L. Nile, Colin Rae, Iain J. Hyndman, Mark N. Gaze and Robert J. Mairs

    Citation: BMC Cancer 2016 16:621

    Content type: Research article

    Published on:

  25. Due to lack of a targeted therapy for the triple-negative breast cancer (TNBC) patients, it is important to explore this aggressive breast cancer type in more detail and to establish novel therapeutic approach...

    Authors: Michaela C. Huber, Rebecca Mall, Herbert Braselmann, Annette Feuchtinger, Sara Molatore, Katrin Lindner, Axel Walch, Eva Gross, Manfred Schmitt, Natalie Falkenberg and Michaela Aubele

    Citation: BMC Cancer 2016 16:615

    Content type: Research article

    Published on:

  26. Chemoresistance is one of the most leading causes for tumor progression and recurrence of bladder cancer. Reactive oxygen species (ROS) plays a key role in the chemosensitivity of cancer cells. In the present ...

    Authors: Xinxing Li, Haolu Wang, Juan Wang, Yuying Chen, Xiaobin Yin, Guiying Shi, Hui Li, Zhiqian Hu and Xiaowen Liang

    Citation: BMC Cancer 2016 16:578

    Content type: Research article

    Published on:

  27. Cell-penetrating peptides (CPPs) are a research hotspot due to their noninvasive delivery ability. Among the identified CPPs, the TAT and R8 peptides have been preferentially applied to transduction into diffe...

    Authors: Lifeng Wang, Haijin Chen, Jinlong Yu, Xiaohua Lin, Jia Qi, Chunhui Cui, Lang Xie and Shuxin Huang

    Citation: BMC Cancer 2016 16:571

    Content type: Research article

    Published on:

  28. Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation of the AKT pathway promotes platinum resistance while inhibition of AKT sensitizes chemoresistant cells. ...

    Authors: Margaret E. Whicker, Z. Ping Lin, Ruth Hanna, Alan C. Sartorelli and Elena S. Ratner

    Citation: BMC Cancer 2016 16:550

    Content type: Research article

    Published on:

  29. The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radioth...

    Authors: Koji Harada, Tarannum Ferdous, Dan Cui, Yasuhiro Kuramitsu, Takuya Matsumoto, Eiji Ikeda, Hideyuki Okano and Yoshiya Ueyama

    Citation: BMC Cancer 2016 16:548

    Content type: Research article

    Published on:

  30. Directly targeting therapeutic suicide gene to a solid tumor is a hopeful approach for cancer gene therapy. Treatment of a solid tumor by an effective vector for a suicide gene remains a challenge. Given the l...

    Authors: Changdong Wang, Yongping Ma, Qiongwen Hu, Tingting Xie, Jiayan Wu, Fan Zeng and Fangzhou Song

    Citation: BMC Cancer 2016 16:545

    Content type: Research article

    Published on:

  31. Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Therefore, nove...

    Authors: Huda A. Al-Howail, Hana A. Hakami, Basem Al-Otaibi, Amer Al-Mazrou, Maha H. Daghestani, Ibrahim Al-Jammaz, Huda H. Al-Khalaf and Abdelilah Aboussekhra

    Citation: BMC Cancer 2016 16:540

    Content type: Research article

    Published on:

  32. Preclinical research indicate that vascular disrupting agent (VDA) treatment induces extensive tumor death but also a systemic mobilization of bone marrow derived cells including endothelial progenitor cells (...

    Authors: Linh Nguyen, Theodora Fifis and Christopher Christophi

    Citation: BMC Cancer 2016 16:533

    Content type: Research article

    Published on:

  33. The use of targeted agents to impel dual inhibition of anti-apoptotic mechanisms and mTOR-mediated pro-survival signaling in colorectal carcinoma (CRC) cell lines with KRAS or BRAF mutation has been shown to indu...

    Authors: Karianne Risberg, Kathrine Røe Redalen, Linda Sønstevold, Tonje Bjørnetrø, Janne Sølvernes and Anne Hansen Ree

    Citation: BMC Cancer 2016 16:531

    Content type: Research article

    Published on:

  34. Success of cancer prodrugs relying on a foreign gene requires specific delivery of the gene to the cancer, and improvements such as higher level gene transfer and expression. Attaining these objectives will be...

    Authors: Jing-Hung Wang, Aaron N. Endsley, Carol E. Green and A. C. Matin

    Citation: BMC Cancer 2016 16:524

    Content type: Research article

    Published on:

  35. We recently demonstrated the cytotoxicity of liquid crystal precursors (hereafter referred to as “mesogenic compounds”) in the human non-small cell lung cancer (NSCLC) cell line A549 which carry wild-type p53....

    Authors: Saori Fukushi, Hironori Yoshino, Atsushi Yoshizawa and Ikuo Kashiwakura

    Citation: BMC Cancer 2016 16:521

    Content type: Research article

    Published on:

  36. Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth o...

    Authors: Meihua Liang, Fei Zhan, Juan Zhao, Qi Li, Jiazi Wuyang, Guannan Mu, Dianjun Li, Yanqiao Zhang and Xiaoyi Huang

    Citation: BMC Cancer 2016 16:504

    Content type: Research article

    Published on:

  37. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard care of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), development of acquired ...

    Authors: Ren Zhao, Shun Zhou, Bing Xia, Cui-ying Zhang, Ping Hai, Hong Zhe and Yan-yang Wang

    Citation: BMC Cancer 2016 16:491

    Content type: Research article

    Published on:

  38. Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to s...

    Authors: Hideo Morioka, Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Mitsuru Takahashi, Tsukasa Yonemoto, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Michiro Susa, Robert Nakayama, Kazumasa Nishimoto, Kazutaka Kikuta, Keisuke Horiuchi…

    Citation: BMC Cancer 2016 16:479

    Content type: Research article

    Published on:

  39. Endocannabinoids have recently drawn attention as promising anti-cancer agents. We previously observed that anandamide (AEA), one of the representative endocannabinoids, effectively inhibited the proliferation...

    Authors: Seok-Woo Park, J. Hun Hah, Sang-Mi Oh, Woo-Jin Jeong and Myung-Whun Sung

    Citation: BMC Cancer 2016 16:458

    Content type: Research article

    Published on:

  40. Approximately 80 % of mesothelioma specimens have the wild-type p53 gene, whereas they contain homozygous deletions in the INK4A/ARF locus that encodes p14 ARF ...

    Authors: Yuanyuan Jiang, Boya Zhong, Kiyoko Kawamura, Takao Morinaga, Masato Shingyoji, Ikuo Sekine, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima and Masatoshi Tagawa

    Citation: BMC Cancer 2016 16:455

    Content type: Research article

    Published on:

  41. Previous work has demonstrated immunomodulatory, anti-tumor, anti-metastatic and anti-angiogenic effects of the small molecule quinoline-3-carboxamide tasquinimod in pre-clinical cancer models. To better under...

    Authors: Adnan Deronic, Sahar Tahvili, Tomas Leanderson and Fredrik Ivars

    Citation: BMC Cancer 2016 16:440

    Content type: Research article

    Published on:

    The Erratum to this article has been published in BMC Cancer 2016 16:610

  42. The natural compound triptolide has been shown to decrease cell proliferation and induce apoptosis and cellular senescence. We previously demonstrated that triptolide decreases tumor formation and metastasis o...

    Authors: Theresa A. Reno, Sun-Wing Tong, Jun Wu, John M. Fidler, Rebecca Nelson, Jae Y. Kim and Dan J. Raz

    Citation: BMC Cancer 2016 16:439

    Content type: Research article

    Published on:

  43. The new modalities for treating patients with non-muscle invasive bladder cancer (NMIBC) for whom BCG (Bacillus Calmette-Guerin) has failed or is contraindicated are recently increasing due to the development of ...

    Authors: Patrick Vianna Garcia, Fábio Rodrigues Ferreira Seiva, Amanda Pocol Carniato, Wilson de Mello Júnior, Nelson Duran, Alda Maria Macedo, Alexandre Gabarra de Oliveira, Rok Romih, Iseu da Silva Nunes, Odilon da Silva Nunes and Wagner José Fávaro

    Citation: BMC Cancer 2016 16:422

    Content type: Research article

    Published on:

  44. Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.

    Authors: N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G. M. Haag, M. Rieger, O. G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran

    Citation: BMC Cancer 2016 16:420

    Content type: Research article

    Published on:

  45. Cancer-cachexia state frequently induces both fat and protein wasting, leading to death. In this way, the knowledge of the mechanism of drugs and their side effects can be a new feature to treat and to have su...

    Authors: André G. Oliveira and Maria Cristina C. Gomes-Marcondes

    Citation: BMC Cancer 2016 16:418

    Content type: Research article

    Published on:

  46. We previously demonstrated that hsa-miR-520d-5p can convert cancer cells into induced pluripotent stem cells (iPSCs) or mesenchymal stem cells (MSCs) via a demethylation process and p53 upregulation in vivo. A...

    Authors: Yoshitaka Ishihara, Satoshi Tsuno, Satoshi Kuwamoto, Taro Yamashita, Yusuke Endo, Keigo Miura, Yugo Miura, Takemasa Sato, Junichi Hasegawa and Norimasa Miura

    Citation: BMC Cancer 2016 16:415

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Cancer 2017 17:666

  47. L-Arg is involved in many biological activities, including the activation of T cells. In breast cancer patients, L-Arg is depleted by nitric oxide synthase 2 (NOS2) and arginase 1 (ARG-1) produced by myeloid-d...

    Authors: Yu Cao, Yonghui Feng, Yanjun Zhang, Xiaotong Zhu and Feng Jin

    Citation: BMC Cancer 2016 16:343

    Content type: Research article

    Published on:

  48. Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions ...

    Authors: Keisuke Takeda, Noboru Hara, Tsutomu Nishiyama, Masayuki Tasaki, Fumio Ishizaki and Yoshihiko Tomita

    Citation: BMC Cancer 2016 16:332

    Content type: Research article

    Published on:

  49. The synthesis of specific, potent progesterone antagonists adds potential agents to the breast cancer prevention and treatment armamentarium. The identification of individuals who will benefit from these agent...

    Authors: Susan E. Clare, Akash Gupta, MiRan Choi, Manish Ranjan, Oukseub Lee, Jun Wang, David Z. Ivancic, J. Julie Kim and Seema A. Khan

    Citation: BMC Cancer 2016 16:326

    Content type: Research article

    Published on:

  50. Transarterial chemoembolization is one of the most widely accepted interventional treatment options for treatment of hepatocellular carcinoma. Still there is a lack of a standard protocol regarding the injecte...

    Authors: Thomas J. Vogl, Elsie Oppermann, Jun Qian, Ulli Imlau, Andreas Tran, Yousef Hamidavi, Huedayi Korkusuz, Wolf Otto Bechstein, Nour-Eldin Abdel-Rehim Nour-Eldin, Tatjana Gruber-Rouh, Renate Hammerstingl and Nagy Naguib Naeem Naguib

    Citation: BMC Cancer 2016 16:325

    Content type: Research article

    Published on:

Submit manuscript

Follow

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us